ESTRELLA IMMUNOPHARMA, INC. Retained Earnings
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Retained Earnings of -$41.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$41.59M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$39.28M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$36.99M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$36.38M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$41.59M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$39.28M 10-Q · filed 2026-05-18 | |
| 2025-12-31 | -$36.99M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$36.38M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$31.58M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$26.03M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$23.93M 10-K · filed 2026-03-18 | |
| 2024-09-30 | -$22.88M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$19.50M 10-KT · filed 2025-03-25 | |
| 2024-03-31 | -$15.55M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$15.08M 10-Q · filed 2024-02-14 | |
| 2023-09-30 | -$14.06M 10-Q · filed 2023-11-20 | |
| 2023-06-30 | -$12.19M 10-K · filed 2024-09-27 | -$2.82M 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$2.53M 10-Q · filed 2023-05-18 | |
| 2022-12-31 | -$2.26M 10-Q · filed 2023-08-01 | |
| 2022-09-30 | -$1.98M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$1.51M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$1.15M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$1.01M 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$870.54K 10-Q · filed 2021-11-10 | |
| 2021-07-19 | -$612.49K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |